Home › Companies › REPARE THERAPEUTICS INC. › 2023-2024
At REPARE THERAPEUTICS INC.'s shareholder meeting held June 17, 2024, in the 2023-2024 proxy season, 53 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 105 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AS… — REPARE THERAPEUTICS INC.'s filing reports the proposal as approved, with 99.9% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: REPARE THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 17, 2024.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and REPARE THERAPEUTICS INC.’s Form 8-K, filed June 17, 2024 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 17, 2024: 4 items on REPARE THERAPEUTICS INC.’s Form 8-K, filed June 17, 2024: 2 elected · 2 approved.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2023-2024
Explore REPARE THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are REPARE THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 17, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Susan M. Molineaux, Ph.D. | 32,268,618 | -- | -- | 14,009 | 3,714,807 | 99.9% | Elected | — |
| Elect Director: Ann D. Rhoads | 31,692,160 | -- | -- | 590,467 | 3,714,807 | 98% | Elected | — |
| 2. Approval, on a Non-Binding, Advisory Basis, of the Compensation of the Company's Named Executive Officers | 32,257,365 | 25,262 | -- | -- | 3,714,807 | 99.9% | Approved | — |
| 3. Appointment of Independent Registered Public Accounting Firm | 35,992,711 | -- | -- | 4,723 | -- | 99.9% | Approved | — |
Source: REPARE THERAPEUTICS INC., Form 8-K, filed with the SEC on June 17, 2024 — read the filing on EDGAR.
Each item below shows how the 53 asset managers that disclosed a REPARE THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 2 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: To elect the two nominees of our board of directors, Susan M. Molineaux, Ph.D. and Ann D. Rhoads, to our board of directors as Class I directors, each to hold office until our Annual Meeting of Shareholders in 2027 and until such director's successor has been duly elected, or if sooner, until the director's death, resignation or removal: Ann D. Rhoads
REPARE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Ann D. Rhoads”): 31,692,160 for, 590,467 withheld, per its Form 8-K filed June 17, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 - Election of Directors Susan M. Molineaux, Ph.D. and Ann D. Rhoads were each elected to serve as a Class I director of the Company's Board of Directors (the "Board") until the 2027 Annual Meeting of Shareholders and until her successor is duly elected or until her earlier death, resigna…”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 9 asset managers below reported 2,747,592 for, 58,592 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ARK ETF Trust | 2,679,341 | 0 | 0 | 0 | For |
| ETF Series Solutions | 0 | 0 | 0 | 47,301 | Withhold |
| HARBOR FUNDS | 45,238 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 19,713 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 11,267 | Withhold |
| State Street | 1,981 | 0 | 0 | 0 | For |
| Fidelity | 704 | 0 | 0 | 0 | For |
| Vanguard | 615 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 24 | Withhold |
Combines 2 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Description as filed by funds: To elect the two nominees of our board of directors, Susan M. Molineaux, Ph.D. and Ann D. Rhoads, to our board of directors as Class I directors, each to hold office until our Annual Meeting of Shareholders in 2027 and until such director's successor has been duly elected, or if sooner, until the director's death, resignation or removal: Susan M. Molineaux, Ph.D.
REPARE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Susan M. Molineaux, Ph.D.”): 32,268,618 for, 14,009 withheld, per its Form 8-K filed June 17, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 - Election of Directors Susan M. Molineaux, Ph.D. and Ann D. Rhoads were each elected to serve as a Class I director of the Company's Board of Directors (the "Board") until the 2027 Annual Meeting of Shareholders and until her successor is duly elected or until her earlier death, resigna…”
Support: 99.9% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 9 asset managers below reported 2,806,160 for, 24 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ARK ETF Trust | 2,679,341 | 0 | 0 | 0 | For |
| ETF Series Solutions | 47,301 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 45,238 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 19,713 | 0 | 0 | 0 | For |
| American Century | 11,267 | 0 | 0 | 0 | For |
| State Street | 1,981 | 0 | 0 | 0 | For |
| Fidelity | 704 | 0 | 0 | 0 | For |
| Vanguard | 615 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 24 | Withhold |
Combines 5 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Description as filed by funds: TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE ACCOMPANYING PROXY STATEMENT.
REPARE THERAPEUTICS INC.’s own tally for this item (“2. Approval, on a Non-Binding, Advisory Basis, of the Compensation of the Company's Named Executive Officers”): 32,257,365 for, 25,262 against — passed, per its Form 8-K filed June 17, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2 -Approval, on a Non-Binding, Advisory Basis, of the Compensation of the Company's Named Executive Officers The shareholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, by the following votes:”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ARK ETF Trust | 2,679,341 | 0 | 0 | 0 | For |
| ETF Series Solutions | 47,301 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 45,238 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 19,713 | 0 | 0 | 0 | For |
| American Century | 11,267 | 0 | 0 | 0 | For |
| State Street | 1,981 | 0 | 0 | 0 | For |
| Fidelity | 704 | 0 | 0 | 0 | For |
| Vanguard | 615 | 0 | 0 | 0 | For |
| Dimensional | 0 | 24 | 0 | 0 | Against |
Fund voting reports, all 9 managers: 2,806,160 for, 24 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BVF INC/IL | 10,333,600 | 0 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 3,232,107 | 0 | 0 | 0 | For |
| Versant Venture Management, LLC | 2,646,657 | 0 | 0 | 0 | For |
| Deep Track Capital, LP | 2,596,917 | 0 | 0 | 0 | For |
| Redmile Group, LLC | 2,016,302 | 0 | 0 | 0 | For |
| MPM BioImpact LLC | 1,389,849 | 0 | 0 | 0 | For |
| Aquilo Capital Management, LLC | 394,740 | 0 | 0 | 0 | For |
| Ensign Peak Advisors, Inc | 365,069 | 0 | 0 | 0 | For |
| Nikko Asset Management Co., Ltd. | 297,636 | 0 | 0 | 0 | For |
| MPM ASSET MANAGEMENT LLC | 182,989 | 0 | 0 | 0 | For |
| HighVista Strategies LLC | 165,173 | 0 | 0 | 0 | For |
| BANK OF MONTREAL /CAN/ | 104,919 | 0 | 0 | 0 | For |
| Renaissance | 57,084 | 0 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 51,091 | 0 | 0 | 0 | For |
| PNC BANK, NATIONAL ASSOCIATION | 46,000 | 0 | 0 | 0 | For |
| Point72 | 33,414 | 0 | 0 | 0 | For |
| BlackRock | 23,758 | 0 | 0 | 0 | For |
| Connor, Clark & Lunn Investment Management Ltd. | 21,959 | 0 | 0 | 0 | For |
| Sand Hill Global Advisors, LLC | 16,904 | 0 | 0 | 0 | For |
| Blue Owl Capital Holdings LP | 13,097 | 0 | 0 | 0 | For |
| American Century | 11,267 | 0 | 0 | 0 | For |
| Two Sigma | 8,422 | 0 | 0 | 0 | For |
| BANK OF AMERICA NA | 7,500 | 0 | 0 | 0 | For |
| CIBC WORLD MARKET INC. | 7,500 | 0 | 0 | 0 | For |
| Allianz | 5,943 | 0 | 0 | 0 | For |
Institutional-manager reports, all 45 managers: 24,045,273 for, 2,489 against. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Description as filed by funds: To appoint Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024, and to authorize our board of directors to fix Ernst & Young LLP's remuneration.
REPARE THERAPEUTICS INC.’s own tally for this item (“3. Appointment of Independent Registered Public Accounting Firm”): 35,992,711 for, 4,723 withheld — passed, per its Form 8-K filed June 17, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3 - Appointment of Independent Registered Public Accounting Firm The shareholders approved the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024, and authorized the Board to fix Ernst & Young LLP's remunera…”
Support: 99.9% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 9 asset managers below reported 2,806,184 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ARK ETF Trust | 2,679,341 | 0 | 0 | 0 | For |
| ETF Series Solutions | 47,301 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 45,238 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 19,713 | 0 | 0 | 0 | For |
| American Century | 11,267 | 0 | 0 | 0 | For |
| State Street | 1,981 | 0 | 0 | 0 | For |
| Fidelity | 704 | 0 | 0 | 0 | For |
| Vanguard | 615 | 0 | 0 | 0 | For |
| Dimensional | 24 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 42,445,406 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | ARK ETF Trust | 6.31% |
| 2 | ETF Series Solutions | 0.11% |
| 3 | HARBOR FUNDS | 0.11% |
| 4 | Harbor ETF Trust | 0.05% |
| 5 | American Century | 0.03% |
| 6 | State Street | <0.01% |
| 7 | Fidelity | <0.01% |
| 8 | Vanguard | <0.01% |
| 9 | Dimensional | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BVF INC/IL | 24.35% |
| 2 | ORBIMED ADVISORS LLC | 7.61% |
| 3 | Versant Venture Management, LLC | 6.24% |
| 4 | Deep Track Capital, LP | 6.12% |
| 5 | Redmile Group, LLC | 4.75% |
| 6 | MPM BioImpact LLC | 3.27% |
| 7 | Aquilo Capital Management, LLC | 0.93% |
| 8 | Ensign Peak Advisors, Inc | 0.86% |
| 9 | Nikko Asset Management Co., Ltd. | 0.70% |
| 10 | MPM ASSET MANAGEMENT LLC | 0.43% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| ARK Investment Management LLC | 4.71% | 13G |
| ANSBERT GADICKE | 4.57% | 13D |
| Renaissance Technologies | 0.83% | 13F |
| Millennium Management | 0.40% | 13F |
| BlackRock | 0.35% | 13F |
| D.E. Shaw | 0.28% | 13F |
| Citadel Advisors | 0.17% | 13F |
| Two Sigma | 0.16% | 13F |
| Dimensional Fund Advisors | 0.10% | 13F |
| Geode Capital | 0.06% | 13F |
Percentages above are of 42,445,406 shares outstanding, as reported by REPARE THERAPEUTICS INC. on its Form 10-Q dated May 3, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from REPARE THERAPEUTICS INC.’s 10-Q dated May 3, 2024. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
REPARE THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page).
proxyvotesnow.com, “REPARE THERAPEUTICS INC. 2024 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/repare-therapeutics-inc/2024 (version of November 9, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.